Skip to main content

Northwest Biotherapeutics Inc

NWBO
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001072379

No open-market purchases or sales by Northwest Biotherapeutics Inc insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $413.6K in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +1 vs. previous quarter
8
13F valueReported value at the end of Q2 2026
$413.6K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding NWBO, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding NWBO at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Northwest Biotherapeutics Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 30, 2024 (view filing)7:49 PM ETJul 264 daysMalik NavidDirectorSSale−657.9K$0.38−$250.0K–23.3M afterDerivative
Dec 1, 2023 (view filing)Nov 16-1715 daysLateMalik NavidDirectorSSale+570.0K$0.8244+$469.9KNew position0 after3 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Northwest Biotherapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.

See all 8 holders
Institutions holding NWBO in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Compass Financial Management LLC1,215,500$227.1K0.03%+1,215,500New
Wall Street Access Asset Management, LLC800,000$149.4K0.02%+600,000+300.0%Added
VSM Wealth Advisory, LLC80,574$15.1K0.00%00.0%Unchanged
Opus Capital Group, LLC60,150$11.0K0.00%00.0%Unchanged
Ethos Financial Group, LLC39,070$6.33K0.00%00.0%Unchanged
Williams Jones Wealth Management, LLC.25,000$4.67K0.00%00.0%Unchanged
Hantz Financial Services, Inc.250$00.00%00.0%Unchanged
Coston, McIsaac & Partners1,000$00.00%00.0%Unchanged